ARS Pharmaceuticals, Inc. (SPRY) Income Statement

The extreme volatility, including a -67.6% sequential decline in 2025Q4, indicates a lack of recurring revenue streams and potential inventory stocking dynamics. While recent quarters show strong year-over-year growth, the pattern is inconsistent, making it difficult to assess underlying demand durability. Investors should monitor whether the company can establish a more stable sales cadence.

The negative gross margin in 2024Q2 suggests a period of significant cost absorption or inventory write-downs, while the subsequent high margins likely reflect favorable product mix or pricing on specific large orders. The recent stabilization around 60-70% may represent a more normalized level, but the historical volatility warrants caution about the sustainability of current profitability.

The scale of SG&A relative to revenue suggests a heavy investment in commercial infrastructure or corporate overhead that is not yet generating proportional sales. While R&D spending is modest and relatively stable, the lack of SG&A leverage as revenue grows indicates that management has not yet demonstrated an ability to scale the business efficiently. This cost structure will require significant revenue growth to overcome.

The company exhibits pronounced negative operating leverage, where the high fixed-cost structure means that revenue growth is currently absorbed by overhead rather than flowing to the bottom line. The operating margin has deteriorated from -3.0% in 2025Q2 to -182.6% in 2026Q2, a trend that must reverse for the business model to become viable. This suggests the current commercial investment phase is consuming capital without yet generating scalable returns.